Livzon Pharmaceutical Group Inc. (FRA:LP6)

Market Cap	3.59B
Revenue (ttm)	1.42B
Net Income (ttm)	256.49M
Shares Out	n/a
EPS (ttm)	0.29
PE Ratio	14.00
Forward PE	13.24
Dividend	0.13 (4.00%)
Ex-Dividend Date	Jun 13, 2025

Volume	n/a
Average Volume	38
Open	3.300
Previous Close	3.300
Day's Range	3.300 - 3.300
52-Week Range	2.760 - 4.300
Beta	n/a
RSI	43.38
Earnings Date	Mar 29, 2026

About FRA:LP6

Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients (API) and intermediates in the People’s Republic of China and internationally. The company offers leuprorelin acetate microspheres, urofollitropin, and menotropins for injection for the assisted reproduction field; Ilaprazole enteric-coated tablets, ilaprazole sodium for injection, and bismuth potassium citrate products for the gastrointestinal field; fluvoxamine maleate and perospirone hydrochloride...

• Industry: Pharmaceutical Preparations
• Founded: 1985
• Employees: 9,067
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: LP6

Financial Performance

In 2024, FRA:LP6's revenue was 11.81 billion, a decrease of -4.97% compared to the previous year's 12.43 billion. Earnings were 2.06 billion, an increase of 5.50%.

Financial numbers in CNY